PL374757A1 - Modulatory receptora CCK-1 - Google Patents
Modulatory receptora CCK-1Info
- Publication number
- PL374757A1 PL374757A1 PL03374757A PL37475703A PL374757A1 PL 374757 A1 PL374757 A1 PL 374757A1 PL 03374757 A PL03374757 A PL 03374757A PL 37475703 A PL37475703 A PL 37475703A PL 374757 A1 PL374757 A1 PL 374757A1
- Authority
- PL
- Poland
- Prior art keywords
- cck
- receptor modulators
- modulators
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39349302P | 2002-07-03 | 2002-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL374757A1 true PL374757A1 (pl) | 2005-10-31 |
Family
ID=30115589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03374757A PL374757A1 (pl) | 2002-07-03 | 2003-07-02 | Modulatory receptora CCK-1 |
Country Status (22)
Country | Link |
---|---|
US (2) | US7037931B2 (pl) |
EP (1) | EP1525190A1 (pl) |
JP (1) | JP2006501194A (pl) |
KR (1) | KR20050042130A (pl) |
CN (1) | CN100522947C (pl) |
AR (1) | AR041183A1 (pl) |
AU (1) | AU2003253776A1 (pl) |
BR (1) | BR0312378A (pl) |
CA (1) | CA2491213A1 (pl) |
CL (1) | CL2003001360A1 (pl) |
CO (1) | CO5400148A1 (pl) |
EA (1) | EA009479B1 (pl) |
HR (1) | HRP20041224A2 (pl) |
IL (1) | IL166069A0 (pl) |
MX (1) | MXPA05000204A (pl) |
NO (1) | NO20050498L (pl) |
NZ (1) | NZ537899A (pl) |
PL (1) | PL374757A1 (pl) |
TW (1) | TW200418469A (pl) |
UA (1) | UA79804C2 (pl) |
WO (1) | WO2004007463A1 (pl) |
ZA (1) | ZA200500973B (pl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA79804C2 (en) * | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
AU2004232973A1 (en) * | 2003-04-18 | 2004-11-04 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
EP1641762A2 (en) * | 2003-07-02 | 2006-04-05 | Janssen Pharmaceutica N.V. | Cck-1 receptor modulators |
US20050020565A1 (en) * | 2003-07-02 | 2005-01-27 | Jones Todd K. | CCK-1 receptor modulators |
WO2005063716A1 (en) * | 2003-12-22 | 2005-07-14 | Janssen Pharmaceutica, N.V. | Imidazoles and their use cck-1 receptor modulators |
WO2006004742A2 (en) * | 2004-06-30 | 2006-01-12 | Janssen Pharamceutica N.V. | α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION |
US7432266B2 (en) | 2004-10-15 | 2008-10-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
US20060177438A1 (en) * | 2005-02-08 | 2006-08-10 | New England Medical Center | Methods of altering absorption of hydrophobic compounds |
AU2007238804A1 (en) * | 2006-04-14 | 2007-10-25 | Merck Sharp & Dohme Corp. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
JP2009533449A (ja) * | 2006-04-14 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | コレシストキニン−1受容体モジュレーターとしての置換イミダゾール4−カルボキサミド類 |
WO2012071310A1 (en) * | 2010-11-24 | 2012-05-31 | The Ohio State University Research Foundation | Integrin-linked kinase inhibitors |
PL3071206T3 (pl) | 2013-11-22 | 2022-01-17 | CL BioSciences LLC | Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie |
CN105722834B (zh) | 2013-12-13 | 2017-12-22 | 豪夫迈·罗氏有限公司 | 酪氨酸蛋白激酶抑制剂 |
JP6219523B2 (ja) | 2013-12-13 | 2017-10-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼの阻害剤 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164381A (en) * | 1986-05-29 | 1992-11-17 | Ortho Pharmaceutical Corporation | Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same |
US4826868A (en) * | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
US5051518A (en) * | 1987-05-29 | 1991-09-24 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides |
AU611437B2 (en) | 1987-05-29 | 1991-06-13 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same |
NZ238912A (en) | 1990-07-17 | 1992-12-23 | Lilly Co Eli | Pyrazole derivatives and medicaments |
ES2152989T3 (es) * | 1993-08-10 | 2001-02-16 | Black James Foundation | Ligandos para los receptores de gastrina y cck. |
US5756529A (en) | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
JPH09151183A (ja) * | 1995-12-01 | 1997-06-10 | Yoshitomi Pharmaceut Ind Ltd | チエニルアミド化合物 |
DE19621687A1 (de) | 1996-05-30 | 1997-12-04 | Bayer Ag | Verfahren zur Herstellung von substituierten Arylpyrazolen |
EP1263753B1 (en) | 2000-03-06 | 2004-05-06 | SmithKline Beecham plc | Imidazol derivatives as raf kinase inhibitors |
GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
GB0011095D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | astrin and cholecystokinin receptor ligands (III) |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
GB0016787D0 (en) * | 2000-07-07 | 2000-08-30 | Pfizer Ltd | Compounds useful in therapy |
DE60141156D1 (de) * | 2000-11-02 | 2010-03-11 | Ajinomoto Kk | Neue pyrazolderivate und diese enthaltende mittel gegen diabetes |
US6784185B2 (en) * | 2001-03-16 | 2004-08-31 | Pfizer Inc. | Pharmaceutically active compounds |
JP2004530690A (ja) * | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
US6750239B2 (en) * | 2001-08-03 | 2004-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
ATE491701T1 (de) * | 2001-08-03 | 2011-01-15 | Vertex Pharma | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
JP2005508320A (ja) | 2001-09-18 | 2005-03-31 | オンコノバ・セラピューティックス・インコーポレーテッド | 1,5−ジアリール−3−置換ピラゾールの調製方法 |
CA2461567C (en) * | 2001-09-19 | 2008-08-19 | Pharmacia Corporation | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
WO2003037336A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
WO2004000788A1 (en) * | 2002-06-19 | 2003-12-31 | Bristol-Myers Squibb Company | Ureido-substituted aniline compounds useful as serine protease inhibitors |
UA79804C2 (en) * | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
-
2003
- 2003-02-07 UA UAA200500955A patent/UA79804C2/uk unknown
- 2003-07-02 CN CNB038207613A patent/CN100522947C/zh not_active Expired - Fee Related
- 2003-07-02 US US10/612,150 patent/US7037931B2/en not_active Expired - Lifetime
- 2003-07-02 NZ NZ537899A patent/NZ537899A/en unknown
- 2003-07-02 WO PCT/US2003/020787 patent/WO2004007463A1/en active Application Filing
- 2003-07-02 KR KR1020057000056A patent/KR20050042130A/ko not_active Application Discontinuation
- 2003-07-02 BR BR0312378-2A patent/BR0312378A/pt not_active IP Right Cessation
- 2003-07-02 CA CA002491213A patent/CA2491213A1/en not_active Abandoned
- 2003-07-02 AU AU2003253776A patent/AU2003253776A1/en not_active Abandoned
- 2003-07-02 EA EA200401621A patent/EA009479B1/ru not_active IP Right Cessation
- 2003-07-02 PL PL03374757A patent/PL374757A1/pl not_active Application Discontinuation
- 2003-07-02 JP JP2004521518A patent/JP2006501194A/ja active Pending
- 2003-07-02 MX MXPA05000204A patent/MXPA05000204A/es active IP Right Grant
- 2003-07-02 EP EP03764341A patent/EP1525190A1/en not_active Withdrawn
- 2003-07-03 TW TW092118137A patent/TW200418469A/zh unknown
- 2003-07-03 CL CL200301360A patent/CL2003001360A1/es unknown
- 2003-07-03 AR ARP030102418A patent/AR041183A1/es unknown
- 2003-07-03 CO CO03056084A patent/CO5400148A1/es not_active Application Discontinuation
-
2004
- 2004-12-29 HR HR20041224A patent/HRP20041224A2/xx not_active Application Discontinuation
- 2004-12-30 IL IL16606904A patent/IL166069A0/xx unknown
-
2005
- 2005-01-28 NO NO20050498A patent/NO20050498L/no not_active Application Discontinuation
- 2005-02-02 ZA ZA200500973A patent/ZA200500973B/en unknown
- 2005-09-19 US US11/230,200 patent/US7465808B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20060014817A1 (en) | 2006-01-19 |
CN1678587A (zh) | 2005-10-05 |
BR0312378A (pt) | 2005-04-26 |
MXPA05000204A (es) | 2005-09-30 |
EA200401621A1 (ru) | 2005-06-30 |
EA009479B1 (ru) | 2008-02-28 |
AR041183A1 (es) | 2005-05-04 |
US20040067983A1 (en) | 2004-04-08 |
EP1525190A1 (en) | 2005-04-27 |
US7465808B2 (en) | 2008-12-16 |
IL166069A0 (en) | 2006-01-15 |
TW200418469A (en) | 2004-10-01 |
NZ537899A (en) | 2007-04-27 |
AU2003253776A1 (en) | 2004-02-02 |
ZA200500973B (en) | 2006-04-26 |
CL2003001360A1 (es) | 2005-06-03 |
CN100522947C (zh) | 2009-08-05 |
WO2004007463A1 (en) | 2004-01-22 |
NO20050498L (no) | 2005-03-16 |
UA79804C2 (en) | 2007-07-25 |
US7037931B2 (en) | 2006-05-02 |
KR20050042130A (ko) | 2005-05-04 |
CA2491213A1 (en) | 2004-01-22 |
HRP20041224A2 (en) | 2007-03-31 |
JP2006501194A (ja) | 2006-01-12 |
CO5400148A1 (es) | 2004-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2384570B (en) | Modulators | |
TWI340738B (en) | Modulators of the glucocorticoid receptor | |
AU2003290778A8 (en) | Non-steroidal farnesoid x receptor modulators | |
EP1581217A4 (en) | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR | |
EP1553963A4 (en) | NOVEL AGENTS MODULATING EPH RECEPTOR ACTIVITY | |
AU2003245773A1 (en) | Vanilloid receptor modulators | |
PL376438A1 (pl) | Środki modulujące receptory wapnia | |
HRP20130638T1 (en) | Cannabinoid receptor modulator | |
GB0400440D0 (en) | Receptor modulators | |
IL159594A0 (en) | Adenosine a3 receptor modulators | |
EP1620453A4 (en) | MODULATION OF GLUCAGON RECEPTOR EXPRESSION | |
PL375559A1 (pl) | Środki modulujące receptory wapnia | |
AU2003237492A1 (en) | Urotensin ii receptor modulators | |
IL166069A0 (en) | CCK-1 receptor modulators | |
AU2002335075A1 (en) | Estrogen receptor modulators | |
EP1641493A4 (en) | RADIOACTIVELY MARKED CANNABINOID-1 RECEPTOR MODULATORS | |
HK1070362A1 (en) | Non-steroidal progesterone receptor modulators | |
IL172921A0 (en) | Cck-1 receptor modulators | |
AU2003231523A1 (en) | Estrogen receptor modulators | |
GB2386965B (en) | Electro-optic modulators | |
EP1581309A4 (en) | KINASE MODULATORS | |
IL173337A0 (en) | Receptor | |
GB0306575D0 (en) | Modulators | |
EP1467739A4 (en) | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONE AS ANDROGEN RECEPTOR MODULATORS | |
AU2003226396A8 (en) | Imidazolidine compounds as chemokine receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |